Multiple Myeloma Hub

48 Episodes

1. When BCMA-directed therapy is not an option, how should we treat late relapse?

   Published: 5/24/2021
2. What do you need to remember when facing CAR T-cell toxicities?

   Published: 4/12/2021
3. What are the key additions to the new NCCN guidelines for multiple myeloma?

   Published: 4/7/2021
4. If maintenance after induction reduces therapy options at relapse, is it still worth it?

   Published: 4/1/2021
5. New findings on the role of the immune microenvironment presented at ASH 2020

   Published: 2/16/2021
6. ASH 2020 discussion: Looking for the best partner for lenalidomide maintenance after auto-SCT

   Published: 2/9/2021
7. Should we still use high-dose melphalan in the era of novel agents?

   Published: 2/9/2021
8. What are the unmet needs in AL amyloidosis in Europe?

   Published: 2/1/2021
9. ASH 2020 discussion: The role of upfront transplant consolidation in the era of novel agents

   Published: 1/27/2021
10. Can single cell sequencing help to better define and monitor MM?

    Published: 12/17/2020
11. My experience with novel immunotherapies

    Published: 11/11/2020
12. How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease

    Published: 7/8/2020
13. Melphalan flufenamide (melflufen) + novel agents for RRMM

    Published: 7/8/2020
14. Isatuximab plus KRd for high-risk NDMM

    Published: 6/24/2020
15. Novel approaches in multiple myeloma: what is unique about CELMoDs?

    Published: 6/24/2020
16. Hot topics in MM: quadruplets and anti-BCMA therapy

    Published: 6/24/2020
17. Genomics of high-risk myeloma

    Published: 6/23/2020
18. The association between the diversity of the oral microbiome and PFS

    Published: 6/22/2020
19. Novel approaches in multiple myeloma: BFCR4350A

    Published: 6/18/2020
20. Update from CARTITUDE-1 | What's new since ASH?

    Published: 6/8/2020